These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27694470)

  • 1. The conundrum of malaria chemoprophylaxis.
    Shanks D
    J Travel Med; 2016 Jun; 23(6):. PubMed ID: 27694470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atovaquone-proguanil chemoprophylaxis in the era of Tafenoquine.
    Meltzer E; Schwartz E
    J Travel Med; 2019 Jun; 26(4):. PubMed ID: 30535377
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness of twice a week prophylaxis with atovaquone-proguanil (Malarone®) in long-term travellers to West Africa.
    Lachish T; Bar-Meir M; Eisenberg N; Schwartz E
    J Travel Med; 2016 Jun; 23(6):. PubMed ID: 27625401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative benefit of malaria chemoprophylaxis modelled in United Kingdom travellers.
    Toovey S; Nieforth K; Smith P; Schlagenhauf P; Adamcova M; Tatt I; Tomianovic D; Schnetzler G
    Travel Med Infect Dis; 2014; 12(6 Pt B):726-32. PubMed ID: 25443997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of atovaquone-proguanil chemoprophylaxis and chloroquine treatment in Plasmodium malariae infection.
    Visser R; de Mast Q; Munnix I; van der Ven A; Dofferhoff T
    Travel Med Infect Dis; 2016; 14(6):644-645. PubMed ID: 27546283
    [No Abstract]   [Full Text] [Related]  

  • 6. Antimalarial pharmacology and therapeutics of atovaquone.
    Nixon GL; Moss DM; Shone AE; Lalloo DG; Fisher N; O'Neill PM; Ward SA; Biagini GA
    J Antimicrob Chemother; 2013 May; 68(5):977-85. PubMed ID: 23292347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atovaquone and proguanil hydrochloride for treatment of malaria.
    Kremsner PG; Looareesuwan S; Chulay JD
    J Travel Med; 1999 May; 6 Suppl 1():S18-20. PubMed ID: 23573548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atovaquone and proguanil hydrochloride for prophylaxis of malaria.
    Shanks GD; Kremsner PG; Sukwa TY; van der Berg JD; Shapiro TA; Scott TR; Chulay JD;
    J Travel Med; 1999 May; 6 Suppl 1():S21-7. PubMed ID: 23573549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-free Holidays: Compliance, Tolerability, and Acceptability of a 3-Day Atovaquone/Proguanil Schedule for Pretravel Malaria Chemoprophylaxis in Australian Travelers.
    Lau CL; Ramsey L; Mills LC; Furuya-Kanamori L; Mills DJ
    Clin Infect Dis; 2019 Jun; 69(1):137-143. PubMed ID: 30281083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Questionnaire-based analysis of atovaquone-proguanil compared with mefloquine in the chemoprophylaxis of malaria in non-immune Japanese travelers.
    Kato T; Okuda J; Ide D; Amano K; Takei Y; Yamaguchi Y
    J Infect Chemother; 2013 Feb; 19(1):20-3. PubMed ID: 22740189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria.
    Nakato H; Vivancos R; Hunter PR
    J Antimicrob Chemother; 2007 Nov; 60(5):929-36. PubMed ID: 17848375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognition and Management of Malaria.
    Gerstenlauer C
    Nurs Clin North Am; 2019 Jun; 54(2):245-260. PubMed ID: 31027664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety of atovaquone-proguanil for the prevention and treatment of malaria in pregnancy: A systematic review.
    Andrejko KL; Mayer RC; Kovacs S; Slutsker E; Bartlett E; Tan KR; Gutman JR
    Travel Med Infect Dis; 2019; 27():20-26. PubMed ID: 30654041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malaria chemoprophylaxis regimens: a descriptive drug utilization study.
    Bloechliger M; Schlagenhauf P; Toovey S; Schnetzler G; Tatt I; Tomianovic D; Jick SS; Meier CR
    Travel Med Infect Dis; 2014; 12(6 Pt B):718-25. PubMed ID: 24934849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapsing malaria: two cases of malaria presenting 8 months after return from Africa despite adherence to antimalarial chemoprophylaxis.
    Morgan GS; Chiodini P; Evans M
    Br J Gen Pract; 2012 Oct; 62(603):555-6. PubMed ID: 23265223
    [No Abstract]   [Full Text] [Related]  

  • 16. New options for the prevention and treatment of malaria: focus on the role of atovaquone and proguanil hydrochloride.
    Shanks GD
    J Travel Med; 1999 May; 6 Suppl 1():S1. PubMed ID: 23573544
    [No Abstract]   [Full Text] [Related]  

  • 17. Further observation of travellers taking twice-weekly atovaquone-proguanil prophylaxis in sub-Saharan Africa.
    Biber A; Harel R; Schwartz E
    J Travel Med; 2019 Jun; 26(4):. PubMed ID: 30690466
    [No Abstract]   [Full Text] [Related]  

  • 18. In Vitro Analysis of the Interaction between Atovaquone and Proguanil against Liver Stage Malaria Parasites.
    Barata L; Houzé P; Boutbibe K; Zanghi G; Franetich JF; Mazier D; Clain J
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4333-5. PubMed ID: 26926628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimalarial chemoprophylaxis and treatment in the USA: limited access and extreme price variability.
    Frosch AE; Thielen BK; Alpern JD; Walz EJ; Volkman HR; Smith M; Wanduragala D; Holder W; Boumi AE; Stauffer WM
    J Travel Med; 2022 Jul; 29(4):. PubMed ID: 34343310
    [No Abstract]   [Full Text] [Related]  

  • 20. On the potential for discontinuing atovaquone-proguanil (AP) ad-hoc post-exposure and other abbreviated AP-regimens: Pharmacology, pharmacokinetics and perspectives.
    Schnyder JL; de Jong HK; Bache EB; van Hest RM; Schlagenhauf P; Borrmann S; Hanscheid T; Grobusch MP
    Travel Med Infect Dis; 2023; 52():102520. PubMed ID: 36526126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.